The Technical Analyst
Aptose Biosciences Inc [APTO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aptose Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.07% $1.231
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 19.35 mill |
| EPS: | -7.58 |
| P/E: | -0.160 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 15.72 mill |
| Avg Daily Volume: | 0.0963 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.160 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.160 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.213 (-1.45%) $-0.0178 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.089 - 1.371 ( +/- 11.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-05 | Payne Fletcher | Buy | 55 000 | Employee Stock Option (Right to Buy) |
| 2024-02-05 | Bejar Rafael | Buy | 35 000 | Employee Stock Option (Right to Buy) |
| 2024-02-05 | Ledru Philippe | Buy | 11 000 | Employee Stock Option (Right to Buy) |
| 2024-02-05 | Rice William G. | Buy | 70 000 | Employee Stock Option (Right to Buy) |
| 2024-02-05 | Seizinger Bernd R. | Buy | 3 333 | Director Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 9 955 760 | Sell: 550 471 |
Forecast:
16:00 - $1.231
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.231
Forecast 2: 16:00 - $1.231
Forecast 3: 16:00 - $1.231
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.231 (-3.07% ) |
| Volume | 0.0363 mill |
| Avg. Vol. | 0.0963 mill |
| % of Avg. Vol | 37.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APTO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Latest Press Releases
2024-03-26 16:01:00 - Press Release
Aptose Reports Results For The Fourth Quarter And Full Year 2023
Tuspetinib to advance to tus+ven+hma triplet therapy pilot study in 1l aml tuspetinib continues broad activity across mutations with excellent safety profile luxeptinib g3 formulation achieves desired levels and positions for future trials conference call and webcast at 5:00 pm et today san diego and toronto, march 26, 2024 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended december 31, 2023, and provided a corporate update. “the data we have generated from tuspetinib thus far – as a single agent and in combination therapy with venetoclax in relapsed and refractory aml – have demonstrated a distinctly favorable safety profile and broad activity for tuspetinib across mutational subtypes.
2024-03-18 16:30:00 - Press Release
Aptose To Report Fourth Quarter And Year End 2023 Financial Results And provide Corporate Update On Tuesday, March 26, 2024
San diego and toronto, march 18, 2024 (globe newswire) -- aptose biosciences inc. (nasdaq: apto; tsx: aps), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended december 31, 2023, on tuesday, march 26, 2024, after the close of the market, and provide a corporate update. conference call & webcast: date: tuesday, march 26, 2024 time: 5:00 pm et audio webcast only: link q&a participant registration link*: link (https://register.vevent.com/register/bie69f08fc83634a6aa38bf7081d82c6a2) *analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique pin, which are required to access the conference call.
2024-01-31 16:01:00 - Press Release
Aptose Announces Closing Of $9.7 Million Public Offering And Concurrent $4 Million Private Placement With Hanmi Pharmaceutical, Including Full Exercise Of Over-allotment Option
San diego and toronto, jan. 31, 2024 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the “public offering”) of 5,649,122 common shares of the company (the “common shares”) and warrants at a combined offering price of us $1.71 per share. this includes 736,842 common shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option.
2024-01-26 08:00:00 - Press Release
Aptose Announces Pricing Of $8.4 Million Public Offering And A Concurrent $4 Million Private Placement With Hanmi Pharmaceutical
San diego and toronto, jan. 26, 2024 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the pricing of an underwritten public offering (the “public offering”) of 4,912,280 common shares of the company (the “common shares”) at a public offering price of us $1.71 per share. each common share will also include a warrant to purchase a common share (a “warrant share”) at a price of $1.71 per warrant share.
2023-12-09 18:30:00 - Press Release
Aptose Tuspetinib Clinical Data Featured In Oral Presentation At The 2023 Ash Annual Meeting
Reporting complete response data from the ongoing aptivate international phase 1/2 study of tuspetinib (tus) in relapsed/refractory aml patients tus single agent and tus/ven combination demonstrate favorable safety and tolerability tus/ven combination active across broad populations of aml and demonstrates 25% complete response rate among all-comers, including 20% crc in wildtype aml tus targets ven resistance mechanisms, enabling tus/ven combination to achieve responses in difficult-to-treat prior-ven failure aml total enrollment of patients receiving tus or tus/ven is now over 160 san diego and toronto, dec. 09, 2023 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that a growing body of clinical data for aptose's lead compound tuspetinib (tus), demonstrates significant benefit as a single agent and in combination with venetoclax (ven) in patients with relapsed or refractory acute myeloid leukemia (r/r aml) in the ongoing aptivate phase 1/2 study...
Latest News
2024-04-05 13:01:13 - Zacks Investment Research
What Makes Aptose Biosciences (APTO) a New Buy Stock
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-26 20:38:02 - Seeking Alpha
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
2024-03-18 16:30:00 - GlobeNewsWire
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Tuesday, March 26, 2024 Time: 5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link (https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2) *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call.
2024-01-26 08:36:20 - InvestorPlace
Why Is Aptose Biosciences (APTO) Stock Down Today?
Aptose Biosciences (NASDAQ: APTO ) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company's shares. Aptose Biosciences is selling 4,912,280 shares of its common stock at a price of $1.71 per share.
2023-11-09 19:22:08 - Seeking Alpha
Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript
Aptose Biosciences Inc. (NASDAQ:APTO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon. My name is Hope, and I will be your conference operator today.
2023-10-30 09:15:00 - GlobeNewsWire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure R/R AML Patients 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients Consistent Favorable Safety with TUS Single Agent and TUS/VEN Doublet SAN DIEGO and TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, released highlights from a clinical update event held today, October 30, 2023, in conjunction with the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held in Estoril, Portugal (the “ESH 2023 Conference”)...
2023-10-26 07:11:00 - GlobeNewsWire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Thursday, November 9, 2023 Time: 5:00 PM ET Audio Webcast Only: link Q&A Participant Registration Link*: link (https://register.vevent.com/register/BIb770b610b0744016870ec2150989ea78) *Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call.
2023-09-18 07:45:00 - GlobeNewsWire
Aptose to Present at the Cantor Global Healthcare Conference
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.
2023-08-24 07:30:00 - GlobeNewsWire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, in New York City.
2023-08-10 23:01:11 - Seeking Alpha
Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript
Aptose Biosciences Inc. (NASDAQ:APTO ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Corporate Communications and Investor Relations William Rice - Chairman, President and Chief Executive Officer Rafael Bejar - Senior Vice President and Chief Medical Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Matthew Biegler - Oppenheimer Li Watsek - Cantor Fitzgerald Soumit Roy - JonesTrading Anish Nikhanj - RBC Capital Markets Operator Good afternoon. My name is Zeda and I will be your conference operator today.